This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB). More specifically, it covers the latest guidance for the interpretation of rapid molecular assays for DR-TB by Cepheid (GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra) and Hain Lifescience (GenoTypeMTBDRplus VER 2.0 and GenoTypeMTBDRsl VER 2.0). Participants can exchange experiences through a course forum. Laboratory experts are available to address key questions via the forum and a dedicated pilot email service. The course is particularly relevant for laboratory experts who perform drug-susceptibility testing (DST) for TB and clinicians who use DST results in their routine clinical practice. We hope this training will help refine your practice, thereby strengthening the global capacity to diagnose DR-TB.
This course is also available in the following language: Русский.
Overview: Addressing drug-resistant tuberculosis (DR-TB) is a global priority to accelerate progress towards the elimination of TB. In many countries, patients with DR-TB are either not diagnosed at all or receive a delayed diagnosis, leading to further spread and increased severity of the disease. WHO-endorsed rapid molecular tests have dramatically improved the speed and quality of diagnosis of DR-TB and should be adopted more widely, complemented with phenotypic alternatives where necessary. This course provides updated guidance for the interpretation of selected genotypic drug-susceptibility testing (gDST) assays, based on a review by the European Laboratory Initiative on TB, HIV and Viral Hepatitis (ELI). Specifically, the training covers the Hain Lifescience GenoTypeMTBDRplus VER 2.0 and GenoTypeMTBDRsl VER 2.0 line probe assays for first- and second-line anti-TB drugs (FL-LPA and SL-LPA) and the Cepheid GeneXpert MTB/RIF (Xpert) and GeneXpert MTB/RIF Ultra (Ultra). The course includes a dedicated interpretation guide and template, developed by ELI, to enable users to implement the substantial changes to the interpretation of both LPAs in their routine diagnostic service. You will first learn about the principles of gDST and the changes to the interpretation of the above-mentioned assays (Modules A and B). We will then focus on how to resolve problems with the LPAs and on how to minimize contamination (Modules C and D).
To complement the practical guidance, each training module has a forum where participants can exchange their experiences. Laboratory experts are available to address key questions through both the forum and a dedicated pilot email service. The most relevant points will be compiled within a dedicated course section on “important updates and frequently asked questions”. This way, the course will be continuously refined based on the feedback from participants and the wider scientific community.
An additional module to explain the reasons for discordances between genotypic and phenotypic DST results and how to resolve them is planned.
Learning objectives: By the end of this course, participants should be able to implement the latest WHO guidelines for the interpretation of Xpert, Ultra, FL-LPA and SL-LPA for gDST.
Course duration: Approximately 5 hours (2 for the online modules and 3 for the practical examples).
Certificates: A Record of Achievement is offered at the end of the course upon passing 80% of test questions.
Disclaimer: All reasonable precautions have been taken by the authors to verify the information contained in this course. However, the published material is being distributed without warranty of any kind, either expressed or implied. Responsibility for the interpretation and use of the material lies with the reader. In no event shall the authors be liable for damages arising from its use.